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Introduction
The yield of the literature this summer is a bit lower than
normal, maybe due to a somewhat more critical selection of
articles. Nevertheless, several interesting new data on recur-
rent lymphoma, the role of viruses, and the superiority of
molecular features over clinical data might be helpful for the
readership of the Journal of Hematopathology.
Biology of lymphoma
B cell lymphomas
Genomic instability is very common in cancer, including lym-
phomas, although the results of instability are rather stable.
The control of the mitotic spindle assembly is therefore a very
relevant process and a complicated one. This process is not
only affected in many cancers but also the target of therapy.
Engel et al. [1] demonstrate that USP9X is the mitotic
deubiquitinase of the X-linked inhibitor of apoptosis protein
(XIAP) and that deubiquitylation and stabilization of XIAP by
USP9X lead to increased resistance toward mitotic spindle
poisons. Furthermore, primary human aggressive B cell lym-
phomas exhibit high USP9X expression, which correlates
with XIAP overexpression and high USP9X/XIAP expression
is associated with shorter event-free survival in patients treat-
ed with spindle poison-containing chemotherapy. Finally,
aggressive B cell lymphoma cell lines with USP9X and
XIAP overexpression exhibit increased chemoresistance, re-
versed by specific inhibition of either USP9X or XIAP.
Therefore, USP9X and XIAP are potential predictive bio-
markers and targets in combined therapeutical approaches in
aggressive B cell lymphoma.
Another approach to discover a potential predictive bio-
marker was used by Joosten et al. [2]. It was reported that only
a subset of patients with B cell respond to histone deacetylase
(HDAC) inhibition. Using an extensive molecular approach
on 26 B cell lines, they found that the Src tyrosine kinase
Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene ho-
molog (FGR) is associated with resistance to HDAC inhibi-
tion. As functional proof, CRISPR/Cas9-mediated FGR
knockout in resistant cells restored sensitivity. In silico analy-
sis of B cell lymphoma samples (n = 1200) showed a wide
range of FGR expression indicating that FGR expression
might help to stratify patients; however, clinical data were
not available, nor results from treatment with HDAC
inhibition.
Mantle cell lymphoma (MCL) is characterized by common
recurrences after therapy. Wu et al. [3] collected primary sam-
ples and recurrences from 13 patients with MCL and used
whole genome sequencing in order to indentify the underlying
genetic basis for recurrent disease. They confirmed that MCL
is genetically heterogeneous (like all cancers) and also that
genetic alterations acquired in the relapse samples are very
different between patients. Juscevicius et al. [4] performed a
similar study in diffuse large B cell lymphoma (DLBCL),
comparing also cases with and without a relapse (20 of each).
In 3 of the patients the relapse appeared actually a new prima-
ry lymphoma. In bona fide relapses, they found 2 distinct
genetic routes: [1] early-divergent/branching evolution from
a common progenitor in 6 patients and [2] late-divergent/lin-
ear progression of relapses in 11 patients. Analysis of
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recurrent genetic events identified potential early drivers of
lymphomagenesis (KMT2D, MYD88, CD79B, and PIM1).
The most frequent relapse-specific events were additional mu-
tations in KMT2D and alterations of MEF2B. SOCS1 muta-
tions were exclusive to non-relapsing DLBCL, whereas pri-
maries of relapsing DLBCL more commonly displayed gains
of 10p15.3-p12.1 containing the potential oncogenes
PRKCQ, GATA3, MLLT10, and ABI1. Melchart et al. [5]
addressed the same question, but used a more limited, targeted
approach with 108 genes enabling the use of formalin fixed
paraffin embedded material of 28 patients. Mutations were
present in 74 of the 104 genes tested. Primary tumor samples
showed a median of 8 mutations (range 0–24) with the used
gene set. Lower numbers of mutations in the primary tumor
were associated with a better median overall survival. They
describe three patterns of clonal evolution toward relapse of
disease: large global change, subclonal selection, and no or
minimal change possibly suggesting preprogrammed resis-
tance. Although, a new primary was not excluded, these re-
sults are in line with those of Juscevicius et al. [4], pattern 1
being comparable with route 2 and patterns 2 and 3 compara-
ble with route 1; because of the fewer genes analyzed, indeed
pattern 3 may actually be a subtle variant of pattern 2.
Lymphomas originating in the thymus, derived from B
cells, form an enigmatic group of entities. B cells are few in
number in the normal thymus and are considered to be the cell
of origin of mediastinal (m)DLBCL, which is confirmed with
more detail by Bergkvist et al. [6]. They investigated the B
cells from the bone marrow and thymus of non-lymphoma
patients, obtained during cardiac surgery. In the thymus, 4 %
(median; range 2–14 %) of the CD45+ cells were CD19+ B
cells, with a major fraction being CD27+/CD38− memory B
cells; for the bone marrow, this was 14 % (median; range 3–
27 %), and only a minor fraction of memory B cells. Global
gene expression analysis of the memory B cell subsets from
the two compartments identified 133 genes higher in thymus,
including AICDA, REL, STAT1, TNF family, SLAMF1,
CD80, and CD86. This thymic memory B cell gene profile
was also more often expressed in primary mDLBCL com-
pared with other types. It would be interesting to know how
these results relate to mediastinal Hodgkin lymphoma (HL)
and the intermediate type (“grey zone”).
T cell lymphoma
Margolsky et al. [7] performed targeted sequencing of 465
cancer-related genes and high-resolution copy number analy-
sis in 19 post-transplant lymphoproliferative disorders
(PTLD) of T or NK cell rare entities and their genetic basis
is unclear. They detected 377 variants detected, with an aver-
age of 20 variants per case. The most frequent alterations were
mutations of epigenetic modifier genes (TET2, KMT2C,
KMT2D, DNMT3A, ARID1B, ARID2, KDM6B),
inactivation of TP53 by mutation and/or deletion and muta-
tions of JAK/STAT pathway genes (n = 5). Complex copy
number changes were detected in 8 of 16 (50 %) cases and
disease subtype-specific aberrations were also identified. In
contrast to B cell PTLDs, the molecular and genomic alter-
ations observed in T/NK-PTLD appear similar to those report-
ed for peripheral T cell lymphomas (PTCL) occurring in im-
munocompetent hosts, which, according to the authors, may
suggest common genetic mechanisms of lymphoma develop-
ment. However, the number of cases is quite low. Boddicker
et al. [8] investigated 148 PTCL with DNA and RNA next-
generation sequencing to identify chromosomal rearrange-
ments encoding expressed fusion transcripts in PTCL. Two
of 11 cases had novel fusions involving VAV1, encoding a
truncated form of the VAV1 guanine nucleotide exchange fac-
tor important in T cell receptor signaling. Fluorescence in situ
hybridization (FISH) studies identified VAV1 rearrangements
in 10 of 148 PTCLs (7 %). These were observed exclusively
in PTCL, not otherwise specified (11 %) and anaplastic large
cell lymphoma (11 %). They also identified novel kinase gene
fusions, ITK-FER and IKZF2-ERBB4, as candidate therapeu-
tic targets that show similarities to known recurrent oncogenic
ITK-SYK fusions and ERBB4 transcript variants in PTCLs,
respectively. Additional novel and potentially clinically rele-
vant fusions also were discovered. The authors conclude that
their identification of VAV1 fusions as recurrent and targetable
events in PTCLs indicates the potential for their sequencing
approach to guide individualized therapy approaches for this
group of aggressive malignancies.
Viruses and lymphoma
The role of several viruses in the pathogenesis of lymphomas
is well known. The presence of a virus even defines some
lymphoma types like Epstein-Barr virus (EBV)-positive
DLBCL of the elderly. However, Monabati et al. [9] add fur-
ther evidence that the age criterium is not relevant and that
“elderly” needs to be omitted (see also [10, 11)]. Out of 95
their DLBCL, 11.6 % were EBV positive (7.5 and 14.5 % in
the young and old groups). They did not find any significant
difference in IHC subclasses and clinical data between EBV-
positive DLBCL of young and old groups. Kadry et al. [12]
compared 100 newly diagnosed Egyptian lymphoma patients
with 100 healthy age- and sex-matched normal controls for
the presence of hepatitis B and C (HBV, HCV) viruses, EBV,
cytomegalovirus (CMV), and human herpes virus-8 (HHV-8).
There was high indication of presence of most viruses in lym-
phoma cases except for positive HBs Ag, positive CMV IgG,
and HHV-8. Surprisingly, no significant difference was found
between Hodgkin (HL) and non-Hodgkin (NHL) patients ex-
cept for HCV antigen, 57 % for HL and 27 % for NHL.
Another virus that is related to lymphomas is the human
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herpes 6 virus (HHV-6), which can remain latent and chronic
in the host cells after primary infection. Kiani et al. [13] found,
using a nested PCR-method, 12/22 (54 %) cases of HL and
8/22 (36 %) NHL to be positive for HHV-6. What this exactly
means with respect to pathogenesis and treatment remains to
be studied.
Plasmablastic lymphoma (PL) is a rare and aggressive
DLBCL commonly associated with EBV-infection that most
often occurs in the context of human immunodeficiency virus
infection. Laurent et al. [14] found that of their 82 PL cases
half were EBV positive and that these had more often a MYC-
rearrangement and a better 2-year event-free survival. Both
the microenvironment (65 %) and the tumor cells (22 and
5 %) showed expression of programmed cell death-1 (PD-1)
and programmed cell death-ligand 1 (PDL-1) with the EBV-
positive cases more often positive. Whether the expression is
related to response to (immune)therapy remains to be studied.
Defining entities
B cell lymphomas
In a series of papers, van den Brand et al. [15–18] draw attention
to the relatively poorly characterized nodal marginal zone lym-
phoma (NMZL). Now, they analyze the role of nuclear factor
kappa B (NF-kappaB) in 20 nodal marginal zone lymphomas
(NMZLs), 20 follicular lymphomas (FLs), and 11 cases of low-
grade B cell lymphoma, unclassifiable (BCL-u; [19)]. Their
NMZLs were diagnosed with strict criteria including expression
of at least one putative marginal zone marker (MNDA and/or
IRTA1; [17]). Cases that showed features of NMZL but did not
fulfill all criteria were included as BCL-u. All FLs were required
to have a BCL2 rearrangement. NF-kappaB-pathway gene mu-
tations were found in 9 NMZLs, with recurrent mutations in
TNFAIP3 andCD79B. In FL,mutationswere found in 12 cases,
with recurrent mutations in TNFRSF14, TNFAIP3, and
CARD11. In BCL-u, mutations were found in 5 cases with
recurrent mutations in TNFRSF14. TNFRSF14 mutations were
present in FL and BCL-u, but not in any of the NMZLs. In the
group of BCL-u, TNFRSF14 mutations clustered with a FL
immunophenotype. These results suggest that TNFRSF14 mu-
tations point toward a diagnosis of FL and can be used in the
sometimes difficult distinction between NMZL and FL, but, of
course, to apply this in diagnostics would require confirmation
in an independent cohort.
Primary mediastinal B cell lymphoma (PMBL) is an entity
of B cell lymphoma distinct from the other molecular subtypes
of diffuse large B cell lymphoma (DLBCL). However, with-
out knowledge of the primary site of presentation this entity
remains difficult to diagnose. Jardin et al. [20] investigated the
prevalence, specificity, and clinical relevance of mutations of
XPO1, which encodes a member of the karyopherin-β nuclear
transporters. XPO1 mutations were present in 28/117 (24 %)
PMBL cases and in 5/19 (26 %) HL cases but absent/rare in
MZL (0/20) or DLBCL (3/197). A higher prevalence (50 %)
of the recurrent codon 571 variant (p. E571K) was associated
with shorter PFS, independent from age, International
Prognostic Index, and bulky mass. The authors conclude that
the XPO1 E571K mutation represents a genetic hallmark of
the PMBL subtype of DLBCL.
Thymocyte selection-associated high-mobility group box
(TOX) is aberrantly expressed in cutaneous Tcell lymphomas.
To evaluate whether TOX is also expressed by cutaneous B
cell lymphomas, Schrader et al. [21] performed TOX immu-
nohistochemistry on skin biopsies of 44 patients with primary
and secondary cutaneous B cell proliferations. TOX was
expressed not only in the reactive follicle center cells of lymph
nodes, tonsils, cutaneous lymphoid hyperplasia, and primary
cutaneous MZL but also by the neoplastic cells of 16/17 pa-
tients with primary cutaneous follicle center lymphoma
(PCFCL) and 7/7 patients with cutaneous manifestations of
systemic FL. Notably, TOX showed a very similar expression
pattern as BCL6. In 4/10 patients with a BCL6(+) primary
cutaneous diffuse large B cell lymphoma, leg type
(PCDLBCL,LT) and in 2/2 patients with a secondary cutane-
ous BCL6(+) diffuse large B cell lymphoma (DLBCL), TOX
was expressed by more than 50 % of the neoplastic B cells. In
contrast, in 3/3 BCL6(−) PCDLBCL,LT, TOX was complete-
ly negative or weakly expressed by a minor proportion of the
neoplastic B cells. In conclusion, TOX is expressed not only
by neoplastic T cells but also by both reactive and neoplastic
follicle center (germinal center) B cells and a proportion of
BCL6(+) PCDLBCL,LT and secondary cutaneous BCL6(+)
DLBCL. The authors concluded that the functional signifi-
cance of TOX expression in reactive and neoplastic B cells
remains to be elucidated. The marker is not very helpful in
differential diagnosis.
New entities/subtypes
IgG4-related disease (IgG4-RD) is mentioned in quite a few of
these literature reviews and is now a recognized fibro-
inflammatory disorder, which may affect many organs, and
often comes to clinical attention due to tumor-like organ
swel l ing. Typical histopathology of IgG4-RD is
lymphoplasmacytic infiltration rich in IgG4-positive plasma
cells (PCs), storiform fibrosis, and obliterative phlebitis.
Patients with sicca symptoms can be misdiagnosed as primary
Sjögren’s syndrome (pSS) instead of IgG4-RD because of
clinical and histopathological similarities. Moreover, an asso-
ciation with lymphoma development is described in both dis-
eases. Vasaitis et al. [22] investigated signs of IgG4-RD in a
population-based cohort of patients diagnosed with pSS com-
plicated by lymphoma from the Swedish Patient Register
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1964–2007 and the Cancer Register 1990–2007 (n = 79). All
lymphoma tissues and available minor salivary gland biopsies
(n = 11) were immunostained for IgG4and evaluated for other
histopathological signs of IgG4-RD. Only one patient of 79
(1.3 %) had >10 IgG4plasmaPCs/high-power field (HPF) in
the lymphoma tissue, and an unspecified low-grade B cell
lymphoma localized in the submandibular gland. This patient
had also other histopathological features of IgG4-RD in the
lymphoma and a surgical lung biopsy taken 5 years before
lymphoma diagnosis and, therefore, fulfilled the criteria for
IgG4-RD. Occasional IgG4positivePCs (<10/HPF) without
signs of IgG4-RD were observed in another six lymphomas.
No IgG4-positivePCs were identified in the minor salivary
gland biopsies. Thus, histopathological findings of IgG4-RD
may rarely co-exist with low-grade malignant B cell lympho-
ma in patients with initially suspected pSS and may occasion-
ally be associated with an underlying IgG4-RD.
Pediatric-type nodal (PTN) FL is a variant of FL character-
ized by limited-stage presentation and invariably benign be-
havior despite often high-grade histological appearance. It is
important to distinguish PTNFL from typical FL in order to
avoid unnecessary treatment; however, this distinction relies
solely on clinical and pathological criteria, which may be var-
iably applied. Louissaint et al. [23] found, using copy number
analysis and exome and/or targeted sequencing of 26 PTNFLs
(16 pediatric and 10 adult), that the most commonly mutated
gene in PTNFL was MAP2K1, encoding MEK1, with a mu-
tation frequency of 43 %. All MAP2K1 mutations were acti-
vating missense mutations localized to exons 2 and 3, which
encode negative regulatory and catalytic domains, respective-
ly. Missense mutations in MAPK1 (2/22) and RRAS (1/22)
were identified in cases that lacked MAP2K1 mutations. The
second most commonly mutated gene in PTNFL was
TNFRSF14, with a mutation frequency of 29 %, similar to
that seen in limited-stage typical FL. PTNFL was otherwise
genomically bland and specifically lacked recurrent mutations
in epigenetic modifiers. Copy number aberrations affected a
mean of only 0.5 % of PTNFL genomes, compared with 10%
of limited-stage typical FL genomes. Importantly, the muta-
tional profiles of PTNFLs in children and adults were highly
similar. Together, these findings define PTNFL as a biologi-
cally and clinically distinct indolent lymphoma of children
and adults characterized by a high prevalence of MAPK path-
way mutations and a near absence of mutations in epigenetic
modifiers. Therefore, like the removal of elderly from EBV-
positive lymphoma, mediastinal from those DLBCL, it seems
pediatric needs to be removed from the PTNFL.
Pitfalls in lymphoma diagnosis
Most B cell lymphomas express the B cell markers CD20,
CD79a, and Pax 5, but occasionally one, two, or even all three
markers are absent while there is genotypically a B cell neo-
plasia, especially anaplastic lymphoma kinase-positive
DLBCL, PL, primary effusion lymphoma, and extracavitary
human herpes virus 8 (HHV8)-positive DLBCL. Yin et al.
[24] selected 34 cases of previously diagnosed B cell lympho-
mas with no or weak expression of CD20, CD79a, and PAX5
and found Oct2 and Bob1 to be positive in 74% (25 of 34) and
85 % (29 of 34) of the cases, respectively. Ninety-four percent
(32 of 34) of the cases expressed at least one of these two
markers. None of the 51 control cases of non-B cell neoplasms
expressed either Oct2 or Bob1. These data confirm that Oct2
and Bob1 may be helpful in defining rare cases of B cell
neoplasia.
Nodal follicular helper T cell-derived lymphoproliferations
(specifically the less common peripheral T cell lymphomas of
follicular type) exhibit a spectrum of histologic features that
may mimic reactive hyperplasia or HL. Alikhan et al. [25]
found that nine of their 10 (90%) peripheral Tcell lymphomas
of follicular type showed a CD3−/dimCD4+ T cell population
constituting 29 % (range 7.9–62 %) of all lymphocytes. Five
of 10 (50 %) had nodular lymphocyte predominant (LP)HL or
lymphocyte-rich classical (c)HL-like morphology with
scattered Hodgkin-like cells that expressed CD20, CD30,
CD15, and MUM1. Three cases had a nodular growth pattern
and three others exhibited a perifollicular growth pattern with-
out Hodgkin-like cells. EBV was positive in 1 of the 10 cases
(10 %). PCR analysis showed clonal T cell receptor gamma
gene rearrangement in all 10 cases. In comparison, 11 of 15
(73 %) angioimmunoblastic T cell lymphomas showed the
CD3−/dimCD4+ population (mean 20 %, range 3–72 %).
Using a threshold of 3 % for CD3−/dimCD4+ T cells, all 15
LPHL and 8 cHL were negative, as were 25 of 26 reactive
lymph nodes. The authors conclude that the high frequency of
CD3− / d imCD4+ abe r r an t T ce l l s i s s im i l a r i n
angioimmunoblastic T cell lymphomas and peripheral T cell
lymphomas of follicular type and is a useful feature in
distinguishing peripheral T cell lymphomas of follicular type
from morphologic mimics such as reactive hyperplasia or
Hodgkin lymphoma.
Prognostic factors in lymphoma
Kim et al. [26] provide data that may turn the molecular clas-
sification of DLBCL into ABC and GBC type from a pure
prognosticator into a predictive marker. They used retrospec-
tive data from 219 newly diagnosed high-risk DLBCL pa-
tients, of whom 81 had received an autologous stem cell trans-
plantation (ASCT) and 138 patients did not. As expected, the
ASCT group had a better survival and patients with the ABC
subtype had an inferior PFS than those with the GCB subtype.
In the non-ASCT group, the ABC subtype showed also a
worse survival, but in the ASCT group, there was no
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difference in survival according to molecular classification.
This result suggests that upfront ASCT may improve the poor
prognosis of non-GCB subtype in high-risk DLBCL.
Wong et al. [27] try to improve the molecular classification
of DLBCL by showing that FOXP2-positive DLBCL indi-
cates poor response to R-CHOP therapy, especially in the
ABC subtype. Although their in vitro work gives a good bio-
logical explanation, it will be difficult to introduce this marker
into practice.
Green et al. [28] have an even larger ambition: they want to
improve the IPI score by adding LMO2 and BCL2 transcrip-
tion levels. Although their statistical approach is sound, it is
even more unlikely that such an approach will enter the clinic.
Duncan et al. [29] take a more traditional approach by
analyzing protein expression of Runt-related transcription
factor-3 (RUNX3) and enhancer of zeste homolog-2
(EZH2), a histone methyltransferase, which has been shown
to mediate silencing of RUNX3. They found in 83 DLBCL
cases loss of RUNX3 in 20 cases; EZH2 expression was ob-
served in 59 cases. RUNX3-negative tumors had a lower sur-
vival. They conclude that further studies are warranted to elu-
cidate the biology and prognostic utility of RUNX3 in
DLBCL, a conclusion that actually is not very promising.
Ancillary techniques
Clonality testing can be very helpful, provided that it is used
correctly. Roepman et al. [30] assessed the routine diagnostic
value of the EuroClonality/BIOMED-2 assay for B cell
clonality on 192 air-dried archived Giemsa-stained smears
obtained by fine needle aspiration from 184 patients. The
clonality assay showed a high accuracy of 93 % for detection
of malignancy, with a sensitivity of 93 % and a specificity of
92 %. All 64 cases with monoclonal Ig heavy chain/Ig kappa
chain rearrangements were confirmed to be malignant by his-
tology or clinical follow-up. Expert re-evaluation of the gene
scan-data changed the definite diagnosis for five cases (3 %),
mainly because of low signals or absence of proper duplicate
results. This study shows that EuroClonality/BIOMED-2 as-
say can successfully be performed on cytological Giemsa-
stained smears and inclusion in daily practice can assist in
better identification of malignant lymphoma, provided that
sufficient expertise is available.
Liew et al. [31] evaluated the value of a digital FISH cap-
ture and imaging system for the detection ofMYC 8q24 trans-
locations using LSI-MYC (a break-apart probe) and MYC
8;14 translocation using IGH-MYC (a fusion probe). The
LSI-MYC probe was tested on tissue sections from 35 patients
and the IGH-MYC probe on 40 patients. Results for LSI-
MYC had a high degree of correlation between traditional
method of FISH analysis and digital FISH analysis. Results
for IGH-MYC had a 100 % concordance between traditional
method of FISH analysis and digital FISH analysis.
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